RxDoctor Payments Data

Cynthia Veyel, APRN

Family · Leitchfield, KYNPI 1386995538

Payments from drug & device makers

$345in general payments, 2019–2025

Across 22 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$103
  • Novo Nordisk$73
  • Novartis$56
  • AbbVie$54
  • Pfizer$27
  • Dexcom, Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca7$103
Novo Nordisk5$73
Novartis4$56
AbbVie3$54
Pfizer1$27
Dexcom, Inc.1$16
Abbott1$16

How this compares

$345 in reported general payments places this provider in the 40th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$73,710
Medicare patients
265
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$36,966
OzempicSemaglutide25$35,991
Tresiba Flextouch U-200Insulin Degludec48$32,845
JardianceEmpagliflozin12$20,576
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$11,088
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt12$10,000
FarxigaDapagliflozin Propanediol13$7,253
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,105
XareltoRivaroxaban11$5,867
Albuterol Sulfate HfaAlbuterol Sulfate60$2,152
HumalogInsulin Lispro11$1,976
SynthroidLevothyroxine Sodium29$1,897
Potassium Chloride64$1,338
Colchicine12$1,272
Cefdinir91$1,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$36,96641 claims
Novo NordiskOzempic$73$35,99125 claims
AstraZenecaFarxiga, Breztri Aerosphere$103$14,35824 claims
AbbVieSynthroid$54$1,89729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,374 family providers in Kentucky.

Other family in Leitchfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →